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Summary
Objective: Implantation of autologous chondrocytes (AC) is a promising option for the treatment of cartilage defects, but problems with cell
harvesting, dedifferentiation, or the donor age limit the clinical outcome. Mesenchymal stem cells (MSC) gain much interest because of their
simple isolation and multipotential differentiation capacity along with their immunosuppressive properties. The latter might introduce tumor
manifestation. The inﬂuence of undifferentiated and chondrogenically differentiated MSC or AC on tumor growth and metastasis formation
was investigated in a murine melanoma model.
Methods: Allogeneic melanoma cells and either syngeneic MSC (C3H10T1/2, transduced with enhanced green ﬂuorescent protein gene) or
AC were co-injected at a distance of 3 cm into the contra lateral groins of ﬁve mice/group, and evaluated macroscopically and histologically
after 4 weeks.
Results: Undifferentiated MSC migrated to the tumor site and induced strong tumor growth and metastasis formation. Even avital MSC pro-
moted tumor growth and spreading, but insigniﬁcantly without detectable MSC at the tumor site. Chondrogenically differentiated MSC did not
migrate and had a signiﬁcantly lower impact on tumor growth and spreading; AC had no measurable inﬂuence on melanoma cells.
Conclusions: Our data suggest that differentiation of MSC reduces MSC-dependent promotion of latent tumors and that native AC do not
introduce any increased risk of tumor growth. The question of how far MSC should be differentiated prior to clinical application should be
addressed in further studies.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Articular cartilage is frequently injured as a result of sports re-
lated trauma, but it has very limited capacity for repair due to
its avascular nature. Therefore, treatment of focal cartilage
defects is very challenging. There are several approaches
to manage this problem as it causes pain and functional dis-
ability. At present, autologous chondrocyte implantation
(ACI) is one of the most favored treatment options1,2. Autolo-
gous chondrocytes (AC) are harvested from the patients by
a cartilage biopsy, expanded ex vivo and are reimplanted
into the cartilage lesion. This procedure could be shortened
and the complication rate might meminimized, if artiﬁcial car-
tilage engineered bymesenchymal stem cells (MSC) is used.
A preoperative cartilage biopsy would be no longer neces-
sary. This potential usage of MSC for cartilage repair is inten-
sively investigated in several animal models3e5.
There are different sources described for MSC, e.g., bone
marrow, umbilical cord tissue, peripheral blood and placen-
ta6e10. These cells can be separated from other tissues by
their adherence characteristics and surfacemarkers, and ex-
pandedmore than 104-fold without loss of their multipotential
differentiation capacity11,12. MSC are identiﬁed by the*Address correspondence and reprint requests to: Bodo Kurz,
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389absence of CD34 and CD45 hematopoietic cell markers.
They stain positive for CD90, endoglin/CD105 and vascular
cell adhesion molecule-1 (VCAM-1/CD106) and SH39,10.
MSC express the major histocompatibility complex (MHC)
class I but do not express MHC class II, B7-1/2, CD40 or
CD40Lmolecules.Anumber of cytokinesand regulatorymol-
ecules that play important roles in the proliferation and matu-
ration of hematopoietic stem cells is also produced13,14. The
C3H10T1/2 cell line applied for our experiments is bonemar-
rowderived and has already been characterized regarding its
mesenchymal stem cell quality15.
MSC isolated from bone marrow aspirates have got multi-
potential differentiation capabilities andare the excellent can-
didates in tissue engineering (TE), but these cells also exhibit
powerful immunosuppressive effects, about 200-fold com-
pared to immunosuppression achieved by common immuno-
suppressants (e.g., cyclosporine A)16. For this reason, MSC
are already used for clinical application in treatment of graft
versus host disease (GVHD) after bone marrow transplanta-
tionwith success17,18. PrimaryMSCare capable of homing to
the bone marrow and survive in the long term19,20. Unfortu-
nately, these systemic immunosuppressive effects could
also result in a high risk of tumor manifestation that is found
in patients receiving immunosuppressants21e24. Some stud-
ies could already show a consecutive tumor growth promo-
tion after implantation of undifferentiated MSC in animal
models, whereas tumor induction has only been described
for embryonic stem cells (ESC)25e28.
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marrow derived MSC (C3H10T1/2 cell line) with or without
further cartilaginous differentiation, as well as mature AC uti-
lized for ACI could display side effects favoring tumor growth
in amurinemelanomamodel. This animalmodel allows to es-
timate the inﬂuenceofMSCandother cells onB16melanoma
cell proliferation within the period of 4 weeks, when these
cells are injected simultaneously into the contra lateral groins.
Ourstudy isbasedonamelanomamodelwhichhasbeende-
scribed previously: we support ﬁndings showing the character-
istic high malignancy of B16 melanoma cells by syngeneic
subcutaneous inoculation in C57BL/6 mice29. Additionally, the
baseline of tumor growth in the control group was determined
after allogeneic melanoma cell inoculation in C3H/He mice
(baseline 30 ml of tumor volume), and subsequently co-injec-
tion of allogeneic melanoma cells and undifferentiated MSC
showed a strong MSC-dependent increase in melanoma
growth and metastases formation, as it has been shown previ-
ously26. TheMSCutilized for our experiments were transduced
with enhanced green ﬂuorescent protein (EGFP) gene carrying
the retroviral vector pBabePuro30. Thus, it waspossible to show
any migration of MSC to the tumor site and their metastases.
Our study shows that chondrogenic differentiation of MSC re-
ducesMSC-dependent promotion of latent tumors, and that na-
tive AC (normally used for ACI) do not introduce any increased
risk for tumor promotion.Material and methods
The experiments done in this study were approved by the regional gov-
ernment of Schleswig-Holstein (Germany), department of farming, environ-
ment and country places.ANIMALSTwo different strains of mice were used according to their MHC antigen
disparity: C3H/He and C57BL/6. Mice were bred in the central animal hus-
bandry of the University Hospital Schleswig-Holstein, Campus Kiel, Ger-
many. They were housed in the facilities of the Victor-Hensen-Haus and
cared for according to the Laboratory Animal Care Guidelines. Thirty twoTable
Statistical analysis of the detected primary tumor volumes 4 weeks after
reference group with allogeneic mice (ALLO: C3H/He) and B16-BL6 me
in this group and therefore been defined as background with a tumor inci
in syngeneic animals (SYN: C57BL/6) and in allogeneic animals (ALLO)
Cartilaginous differentiation of MSC (MSC-C) decreased the promotion of
of differentiation was clearly observed when native autologous chondroc
melanoma model. EGFP: cells were transduced with EGFP gene. Non-t
CM-Dil also favored tumor growth and metast
Group name Tumor volume [ml],
n¼ 5 animals/group
Mean
[
1 2 3 4 5
Injection of B16
melanoma
cells alone
B16-ALLO/- 12 30 0 0 0
B16-SYN/- 112 178 96 150 148 1
Co-injection of
B16 melanoma
cells with MSC
B16-ALLO/
MSC-EGFP
105 250 200 186 60 1
B16-ALLO/
MSC-EGFP-AV
32 74 0 16 0
B16-ALLO/
MSC-C-EGFP
60 105 36 48 30
B16-ALLO/
MSC-CM-Dil
96 68
Co-injection of
B16 melanoma
cells with AC
B16-ALLO/
AC
22 7 16 0 0adult animals aged 8e12 weeks were used and distributed among seven ex-
perimental groups [ﬁve animals (or two)/group, see Table I]. Three mice
(C3H/He) aged 2 weeks were used for isolation of AC.CELL CULTUREThe murine C3H10T1/2 MSC line and the B16-BL6 melanoma cell line
were kindly given by Mrs. Danie`le No¨el (INSERM U475, Montpellier,
France). These cells were each cultured in complete Dulbecco Modiﬁed Ea-
gle Medium (DMEM, Sigma, Germany) supplemented with 10% fetal calf se-
rum (FCS, Seromed, Germany), 2 mM glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin and 100 mg/ml amphotericin (Seromed, Germany).
Any in vitro contamination of the different cells lines was avoided.EGFP-GENE TRANSDUCTION IN MSCWe successfully performed the stable ﬂuorescent labeling of the MSC
with a retroviral system (pBabePuro). The retroviral vector consists of an in-
ternal ribosome entry site (IRES) element, an EGFP gene and a puromycin
resistant gene for later selection of effectively transduced MSC. MSC were
best transduced after incubation with the retroviral particles for 2 days. Not
transduced cells were killed with 300 mg/ml puromycin (Seromed, Germany)
within 4 days. MSC cell clones with high EGFP production were selected af-
ter punctual trypsinization from the monolayer culture (>99% EGFP-positive
cells) and expanded for the animal experiments [Fig. 1(A, B)].CARTILAGINOUS DIFFERENTIATION OF MSC AND RT-PCRFor cartilaginousdifferentiation 750,000EGFP-gene-transducedC3H10T1/2
MSC were cultured in three-dimensional high density pellets at the bottom of an
Eppendorf cap (Sarstedt, Germany) as described by Kurz et al.31. The differen-
tiationmedium contained the chondrogenic differentiation supplements: 0.1 mM
dexamethasone and 10 ng/ml murine transforming growth factor (TGF-ß1)
(Sigma, Germany). These pellets were exposed to 5% oxygen over a period of
10 days under otherwise normal culture conditions. The morphogenic genotype
of the cells was conﬁrmedbyRT-PCR for aggrecanand collagen type II. Expres-
sion of collagen type II was negative in undifferentiated MSC, while there was
a clear signal in cartilaginous differentiated MSC as well as in AC [Fig. 1(C)].
TheEGFPproductionbyMSCwasnot changedafter cartilaginousdifferentiation
(not shown). Prior to injection the cells were isolated from the pellets by collage-
nase treatment and subsequent ﬁltration through a nylonmesh; cell viability and
number were evaluated as described below.
RNAwas isolated from the cell cultures using the Qiagen RNeasyMini-Kit ac-
cording to themanufacturer’s instructions. Lysedsampleswere homogenizedus-
ing the QIAshredder spin columns (Quiagen). Isolated RNA was determined for
quantity and quality spectrophotometrically (260 and 280 nm). cDNA wasI
treatment using the student’s t test. The group B16-ALLO/- is the
lanoma cells: tumors with a volume of up to 30 ml had been found
dence of 0%. The promotion of tumor growth was highly significant
receiving syngenic undifferentiated MSC (isolated from C3H/He).
tumor growth, and even more the injection of MSC-AV. The impact
ytes (AC: isolated from C3H/He) were co-injected into the murine
ransduced MSC that were labeled with the fluorescent cell-tracker
asis formation. SD ¼ standard deviation
volume
ml]
SD [ml] Incidence
[%, based on tumor volume]
Student’s t test
(a< 0.05)
Tumor Metastasis P value
18 13 0 0 Control
37 33 100 100 <0.0001
60 76 100 80 <0.003
24 31 40 40 0.316
56 30 80 0 0.012
82 20 100
9 10 0 0 0.937
Fig. 1. A, B, and C: EGFP-gene-transduced MSC in monolayer culture after selection. A: phase contrast microscopy, B: ﬂuorescence micros-
copy of the same cells, C: overlay of Aþ B. D: RT-PCR gel showing aggrecan and collagen type II-speciﬁc bands: characterization of native
chondrocytes (1), cartilaginously differentiated MSC (2 and 3) and undifferentiated MSC (4) prior implantation into the animals for expression
of collagen type II (268 bp and 472 bp) and aggrecan (shown for native chondrocytes, 356 bp).
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er’s instructions. For PCR the following bovine primers were used (0.5 g mM):
collagen type II (Sense: GATCTGCACTGAATGGCTGA, Antisense:
TCTGCCCAGTTCAGGTCTCT, product: 472 bp, annealing temperature:
62C), aggrecan (Sense: AGGAGACCCAGACAGCAGAA, Antisense: ACAGT-
GACCCTGGAACTTGG, product: 356 bp, 64C). RT-PCR reaction conditions
were: reverse transcription 30 min, 50C; initial activation step 15 min, 95C; 3-
step cycles: melting 30 s 94C, annealing 60 s primer speciﬁc temp. (59e64C,
see above); a ﬁnal extension step 10 min 72C. Ampliﬁed products were sepa-
rated on a 2% agarose gel, visualized ﬂuorometrically and digitised.THE ISOLATION OF AUTOLOGOUS CHONDROCYTES (AC)Samples of cartilage from the knee joints epiphysis of 2 weeks old mice
(C3H/He) were submitted to a standard collagenase digestion process accord-
ing to the protocol of Kurz et al.32. The cell yield of chondrocytes was about
12 104 per mouse. Isolated chondrocytes were seeded in a density of
100,000/cm2 and cultured for up to 10 days in monolayer for expansion in
DMEM supplemented with 10% FCS, 2 mM glutamine, 100 mg/ml penicillin,
100 mg/ml streptomycin, 100 mg/ml amphotericin, and passaged one to two
times in order to receive a substantial amount of cells. The differentiation of
the cells as chondrocytes was veriﬁed using RT-PCR for extracellular matrix
molecule mRNA of collagen type II and aggrecan. ACwere washed with phos-
phate buffered saline (PBS), trypsinized, centrifugated by a speed of 300 g
during 5 min and resuspended in PBS for cell counting and injection into mice.CELL STAINING WITH CM-DILStock solution of the ﬂuorescent cell-tracer CM-Dil (Molecular Probes, Eu-
gene, OR) was reconstituted at a concentration of 1 mg/ml in dimethylsulfox-
ide (DMSO). Cells were trypsinized, washed with PBS, and resuspended at
the concentration of 107 cells/5 ml in 2 mg CM-Dil/ml PBS, prepared extem-
porarily. Cells were labeled by an incubation at 37C for 5 min followed by
15 min at 4C, in the dark. Unincorporated ﬂuorescent dye was then re-
moved by centrifugation at 300 g for 5 min and two washes in PBS. Cells
were resuspended in PBS and maintained at 4C until injection.THE MURINE MELANOMA MODELB16 melanoma cells, MSC and AC were each prepared as a single-cell
type suspension in separate tubes (5 105 cells in 100 ml PBS). The cellcount and vitality (>90% vitality) was assessed by trypan blue exclusion
with the help of the Neubauer chamber shortly before application. Subcuta-
neous application of the B16 melanoma cells was always performed sepa-
rately into the right groin of the animals. The MSC or AC were given also
subcutaneously as a co-injection at a distance of about 3 cm into the left
groin. This means that melanoma cells on one side and MSC or AC on
the other side where two distinct cell preparations injected in the same
mouse, but not as a mixed preparation. Mice were examined two times
a week and tumor incidence was evaluated by inspection and palpation. Af-
ter 4 weeks animals were sacriﬁced and tumors and metastases were recov-
ered. The length and diameter of melanoma tumors were measured in order
to calculate tumor volumes prior to the histological analysis.HISTOLOGYTumor samples and samples of some major organs (inguinal skin, brain,
bone, lung, spleen, stomach, kidney, liver, peritoneum and gut) were ﬁxed in
4% formaldehyde solution for several days and then processed for routine
histology. Parafﬁn-embedded tissue sections (5 mm) were rehydrated and ei-
ther stained with hematoxylineeosin (HE) before examination or mounted in
ﬂuorescent mounting medium (Dako, Germany) for ﬂuorescence visualiza-
tion of EGFP-transduced cells.STATISTICAL ANALYSISIn this study, results are given as absolute values, mean values and
standard deviation. For statistical analyses the Student’s t test (two-tailed,
unequal variance) was performed with the software program ‘‘XLSTAT
2008’’. A value of P< 0.05 was considered signiﬁcant.ResultsTHE B16 MELANOMA CELLS ARE VERY MALIGNANT IF
INOCULATED IN SYNGENEIC ANIMALSTo demonstrate the vitality and malignancy of B16 mela-
noma cells 5 105 of these cells were injected into the right
groin of the mice. The tumor incidence in syngeneic mice
was 100% just after 2 weeks by palpation (Fig. 2). B16
Fig. 2. Palpated tumor incidence. Five animals/group were treated
according to the murine melanoma model with either one injection
of 5 105 B16 melanoma cells into the right groin or an additional
co-injection of 5 105 MSC or AC into the contra lateral groins.
They were examined twice a week for palpable tumors. Tumor de-
velopment was rapid in syngeneic animals (B16-SYN/-), where the
animals had to be sacriﬁced already after 2 weeks because of suf-
fering. Palpable tumors were also found in animals receiving co-in-
jection of undifferentiated MSC (B16-ALLO/MSC-EGFP) after 10
days and in two cases receiving cartilaginously differentiated
MSC (B16-ALLO/MSC-C-EGFP) after 14 days, whereas no tumor
was palpable in the control group (B16-ALLO/-), or in case of co-in-
jection of MSC-AV (B16-ALLO/MSC-EGFP-AV) or native chondro-
cytes (B16-ALLO/AC). EGFP: cells were transduced with EGFP
gene. Non-transduced MSC that were labeled with the ﬂuorescent
cell-tracker CM-Dil also favored tumor growth and metastasis
formation.
392 I. Akay et al.: Tumor risk by TEmelanoma cells rapidly developed tumors and metastases
in syngeneic C57BL/6 mice, because they are poorly immu-
nogenic. The animals had to be sacriﬁced after 2.5 weeks
since they seemed to suffer much from the melanoma tu-
mor and its metastases. There were many large metastases
formations as described for lymphatic and cavernous tumor
cell spread, although the mean tumor volume was only
137 ml at that time point (Table I and Fig. 3). The incidence
of metastases formation was 100%. There were also
1e2 mm large subcutaneous satellite metastases.THE B16 MELANOMA CELLS ARE REJECTED BY ALLOGENEIC
MICEAllogeneic animals were able to reject B16 melanoma
cells (5 105) injected into the right groin. There were no
metastases in tissue samples of these animals and subcu-
taneous primary tumors had a maximum tumor volume of
30 ml after 4 weeks. Therefore, the baseline for tumor
growth was set to >30 ml and the tumor incidence was de-
ﬁned as 0%, if the primary tumors were not bigger than the
baseline volume (Table I and Fig. 3).THE B16 MELANOMA CELLS ARE NOT REJECTED BY
ALLOGENEIC MICE WHEN CO-INJECTED WITH
UNDIFFERENTIATED MSCIn the presence of undifferentiated MSC co-injected into
the contra lateral groin at a distance of about 3 cm the tumor
volume increased signiﬁcantly (P< 0.003 for ALLO/MSC-
EGFP; Table I). The incidence of tumor growth ormetastases
formation was 100%. Even in two mice which were treated
with un-transduced but CM-Dil-labeled MSC the MSC pro-
moted tumor growth, indicating that tumor progression was
not an unspeciﬁc result of cell transduction (Table I). The
EGFP-gene-transduced or CM-Dil stained MSC weredetectable at the tumor site and within its metastases under
the ﬂuorescence microscope indicating migration of the
MSC (Fig. 4). All primary tumors and all metastases in these
experimental groups demonstrated a strong inﬁltration by la-
beled MSC, although the MSC were primarily located at the
edges of the tumors. We did not see any migration of these
cells into other tissue samples lacking metastases.
We also investigated whether avital (AV) lyophilized MSC
exhibit the sameeffects. After destruction of themigration abil-
ity (there were no MSC visible at the tumor site, Fig. 4), the
mean tumor volume declined to 24 ml (Table I). However, in
two cases tumor growth exceeded the baseline of 30 ml tumor
volume and metastases formation was detectable. Therefore
the incidence of tumor growth and metastases formation was
40%, although promotion of tumor growth by avital MSC
(MSC-AV) was insigniﬁcant (P¼ 0.316). The little butmeasur-
able positive effect on tumor growth and metastasis formation
could probably be attributed to soluble factors of MSC.THERE IS NO SIGNIFICANT INCREASE IN B16 MELANOMA
TUMOR GROWTH AFTER CO-INJECTION OF CARTILAGI-
NOUSLY DIFFERENTIATED MSCIn this set of experiment we co-injected 5 105 melanoma
cells and 5 105 cartilaginously differentiatedMSC subcuta-
neously into the contra lateral groins. At the end of the exper-
iment, the incidence of tumor growth was still 80% (due to the
deﬁnition that every primary tumorwhich exceeds the volume
of 30 ml is deﬁned as tumor formation), but formetastases 0%
(Table I). However, the mean tumor volume was 56 ml only,
and compared to the group of animals receiving undifferenti-
atedMSC (mean tumor volume160 ml) the tumor volumewas
signiﬁcantly diminished (P¼ 0.022). Additionally, no cartila-
ginously differentiated MSC were visible at the tumor site,
indicating loss of migration properties (Fig. 4).THERE IS NO SIGNIFICANT PROMOTION OF B16 MELANOMA
TUMOR GROWTH WHEN CO-INJECTED WITH ACWith this set of experiments we investigated whether AC
have an inﬂuence on tumor growth or metastasis formation
as it is demonstrated for undifferentiated MSC in this study.
AC were successfully isolated from femur epiphyses of
2-week-agedmice. The cartilage characteristics were shown
by RT-PCR. In contrast to undifferentiated MSC the cells
were positive for collagen type II [Fig. 1(C)] and aggrecan
mRNA. The mice received a co-injection of 5 105 B16 mel-
anoma cells with 5 105 AC into the contra lateral groins. At
theendof theexperiment, the incidenceof both, tumor growth
andmetastases, was 0%. Themean tumor volumewas 26 ml
and similar to that of the control group with only allogeneic
B16melanoma cell inoculation and therefore below the base-
line of the promotion of tumor growth (Table I and Fig. 4).Discussion
In our study we explored the potential promotion of tumor
growth and metastasis formation from latent melanoma
cells introduced by MSC or AC in a murine melanoma
model. Both cell types are already utilized in regenerative
medicine: the latter for repair of cartilage defects as used
in ACI1,2 and undifferentiated MSC for the treatment of
GVHD, transplant rejection and autoimmune diseases be-
cause of their potent immunosuppressive effects16e18,33e36.
Unfortunately, these side effects of MSC could display the
promotion of latent malignant tumors under certain
Fig. 3. Macroscopic and histological ﬁndings in the control groups. A1, B1, and A3 show scales for mm. (A1eA3) Large tumors and metas-
tases were recovered in animals of the positive control (B16-SYN/-) that was carried out to explore the high malignancy of B16 melanoma cells
in syngeneic mice. These animals were treated with subcutaneous injection of 5 105 B16 melanoma cells into the right groin. (A1) A large
primary tumor is visible in the subcutaneous tissue. (A2, bar¼ 160 mm) The histological analysis shows part of an isolated round tumor with
necrotic zones (X) which indicate high expansion of the tumor cells. (A3) A spleen metastasis is shown exemplarily. (B1eB3) In the negative
control (B16-ALLO/-) allogeneic animals were treated with subcutaneous injection of B16 melanoma cells. (B1) A small subcutaneous mel-
anoma cell cumulus is visible. (B2, bar¼ 20 mm) Cells in the tumor are plump and ﬁlled with large amount of melanin pigments (arrows).
(B3) No metastasis was detectable in the negative group.
393Osteoarthritis and Cartilage Vol. 18, No. 3circumstances and accelerate their manifestation in MSC-
transplanted patients as noticed after administration of
immunosuppressants. The tumor risk for immunocompro-
mised patients is set 90-fold for lymphoma, 37-fold for ma-
lignant melanoma and 14-fold for cervical cancer21e24. One
should also recapitulate case reports that showed sponta-
neous tumor regression in immunocompetent patients with
prior diagnosis of bronchial carcinoma, gut tumors, malig-
nant melanoma or breast cancer37e41. For review see Blatt-
man and Greenberg42.
Tumor growth promotion by undifferentiated MSC has
been demonstrated in different animal models21,22. The
goal of this study was to estimate the inﬂuence of cartilagi-
nously differentiatedMSCaswell as the inﬂuence of differen-
tiated AC on B16 melanoma tumor growth in vivo. Prior to
administration in the animal experiments, the MSC were
labeledwith EGFP-gene transduction via the retroviral vector
pBabepuro or labeled with CM-Dil (Chloromethylbenzamido
derivative, Invitrogen) as described in prior studies12. We
did not see any morphological or proliferative changes of
these cells after transduction or CM-Dil staining. EGFP ex-
pression was stable in vitro as well as in vivo. We preferred
EGFP cell labeling because of its stability, good detectability
in histological tissue samples and no adverse effects at the
side of injection. In comparison, animals receiving CM-Dil-la-
beled MSC displayed a dermatitis at the injection site. How-
ever, it cured over a period of 2 weeks without any
treatment. Thedetection ofCM-Dil-labeledMSCwasvery dif-
ﬁcult because of autoﬂuorescence and weak CM-Dil-ﬂuores-
cence. It can be therefore concluded that EGFP-gene
transduction of MSC improves the conditions for both cell ap-
plication and subsequent detection of the labeled cells.
In the murine melanoma model, we ﬁrst investigated
whether undifferentiated MSC from passages three to ﬁve
promote tumor growth if co-injected subcutaneously withmelanoma cells at a distance of about 3 cm into the contra
lateral groins of the animals. At the end of the experiment,
we noticed that undifferentiated MSC favored the tumor
growth signiﬁcantly (P< 0.003) and were detectable at the
tumor site and even inside the metastases. Our results
are in concordance with prior studies that explored the tu-
mor risk for MSC in diverse animal models25,26. Addition-
ally, we explored whether maturation of MSC could
inﬂuence the promotion of tumor growth. After cartilaginous
differentiation of the MSC tumor growth favoring was signif-
icantly diminished (P¼ 0.022), and there were no EGFP-
gene-transduced MSC detectable inside or close to the sub-
cutaneous tumors. This suggests that differentiation of MSC
reduces the ability of the cells to migrate and to promote tu-
mor growth. These results, especially a signiﬁcant promo-
tion of tumor growth in the case of non-EGFP-transduced,
CM-Dil-labeled MSC indicate that any immunomodulation
by EGFP-gene transduction reported in further studies is
non relevant in this tumor model43,44.
However, it has to be mentioned that differentiation of the
cells might have inﬂuenced the cell stability or viability (even
though the latter had been evaluated prior to injection). The
reduced inﬂuence of differentiated MSC in this study could
therefore be not only the result of differentiation but also re-
duced cell activity or viability.
We therefore used AV lyophilized undifferentiated MSC
to ﬁnd out whether vitality and the ability to migrate are es-
sential for promotion of the tumor growth. To our knowl-
edge, we are the ﬁrst group using MSC-AV in a murine
melanoma model. We could show that even MSC-AV
seem to promote tumor growth and metastases formation,
even though insigniﬁcantly (P¼ 0.316). The residual posi-
tive effect could be referred to soluble factors within the lyo-
philisate administered subcutaneously to the animals. One
should consider that the immunosuppressive effects of
Fig. 4. Macroscopic and histological ﬁndings of tumor growth after 4 weeks of treatment in the allogeneic (ALLO) mouse melanoma model.
A1eE1, A4, B4 and E4 show scales for mm. Pictures AeE1 show examples of primary tumors in the subcutaneous tissue, AeE2 and AeE3
show corresponding tissue areas of isolated tumors with HE staining (2) or ﬂuorescence microscopy (3), pictures AeE4 show examples of
metastases, if present. (A1eA4) Two of ﬁve animals receiving 5 105 MSC-AV together with 5 105 B16 melanoma cells developed tumors
and metastases. (A2eA3, bars¼ 25 mm) No EGFP-gene-transduced MSC are visible at the tumor side. (A4) A spleen metastasis is shown in
the circled area. Similar tumor growth promotion and migration behaviour was found for non-transduced CM-Dil-labeled undifferentiated MSC
when co-injected with B16 melanoma cells (E1eE4, bars¼ 20 mm). (B1eB4) Animals treated with vital MSC and B16 melanoma cells show
primary tumors in ﬁve of ﬁve cases and metastases in four of ﬁve cases. (B2eB3, bars¼ 20 mm) EGFP-positive MSC (arrows) are detectable
in tissue samples of the primary tumor. (B4) A lung metastasis is demonstrated in the circled area. (C1eC4, bars¼ 20 mm) Animals receiving
co-injection of cartilaginously differentiated MSC (MSC-C) showed small primary tumors in four of ﬁve animals without any indication of MSC
migration to the tumor site or metastasis formation. (D1eD4) No metastases were recovered in animals treated with native autologous chon-
drocytes (AC) and melanoma cells in the presence of remarkable minimal primary tumors similar to that of the control group. (D2, bar¼ 20 mm)
Arrows show melanin pigments.
395Osteoarthritis and Cartilage Vol. 18, No. 3MSC have been attributed to inhibition of T-cell proliferation
and generation of CD8þ regulatory cells by secretion of sol-
uble factors in cocultures31. However, the exact mechanism
of the immunosuppressive effects is still unknown. It should
also be considered that vital undifferentiated MSC might
proliferate in contrast to lyophilized MSC. Therefore, promo-
tion of tumor growth by MSC-AV might be reduced because
of a decreased amount of relevant factors.
In addition, we explored whether AC exhibit similar ef-
fects on tumor promotion when administered in the murine
melanoma model as described above for MSC. In animals
receiving AC, we did not notice any signiﬁcant promotion
of tumor growth compared to the control group treated
with allogeneic B16 melanoma cells without co-injection
(P¼ 0.937). Thus, we were able to show that AC, which
were passaged one to two times do not promote tumor
growth and that promotion of tumor growth is a phenomena
observed for MSC, especially for undifferentiated MSC.
The results of this paper assume that there is apossible risk
of promotion andmanifestation of latent malignant tumors af-
ter administration of MSC, even locally. These effects are
probably related to the low maturation grade or proliferation
capacity of these cells. Therefore, the differentiation proce-
dures of MSC and the mechanism of tumor growth promoted
by MSC should be extensively explored as presumption for
functional tissue produced by TE. Since C3H10T1/2 is
a MSC line generated from mouse embryos, it is suggested
that further studies should demonstrate the inﬂuence of adult
MSC on tumor growth of latent tumors dependent on the sta-
tus of differentiation. PassagedAC, on the other hand, did not
show any promotion of tumor growth and do therefore not in-
troduce any latent risk of tumor manifestation in transplanted
patients. However, the cells used here still showed some col-
lagen type II mRNA expression. AC, that are often used for
treatment of cartilage defects (e.g., ACI), may sometimes
be completely dedifferentiated, and the impact of this dedif-
ferentiation should be investigated in further studies.Conﬂict of interest
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